LRPA
CTSO icon

L. Roy Papp & Associates’s Cytosorbents Corp CTSO Stock Holding History

L. Roy Papp & Associates’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,000
Closed -$86K – 175
2019
Q2 		$86K Buy
+13,000
New +$89.3K 0.01% 170

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

L. Roy Papp & Associates's CTSO Position: Q3 2019 in Review

L. Roy Papp & Associates sold out of Cytosorbents Corp (CTSO) in Q3 2019, closing a stake of 13,000 shares — an estimated $86K sold.

L. Roy Papp & Associates first reported a position in CTSO in Q2 2019 and held it in 1 quarter. The position peaked at $86K in Q2 2019. 69 funds tracked by Wall St. Rank hold CTSO as of Q3 2019.

  • L. Roy Papp & Associates reported no remaining Cytosorbents Corp position as of Q3 2019 after selling out during the quarter.
  • L. Roy Papp & Associates sold 13,000 Cytosorbents Corp shares in Q3 2019, an estimated $86K.
  • L. Roy Papp & Associates first reported a position in Cytosorbents Corp in Q2 2019 and held it in 1 quarter.
  • L. Roy Papp & Associates's Cytosorbents Corp position peaked at $86K in Q2 2019.
  • 69 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2019.

Based on L. Roy Papp & Associates's 13F filing for Q3 2019, filed 4 Nov 2019.